Keywords
How to Cite
Abstract
Immune checkpoint inhibitors are the most promising treatment option for many histological subtypes of malignant tumors, providing a long objective response and an increase in overall survival. Currently, there is growing evidence of the specific heterogeneity of clinical and radiological responses to immunotherapy, such as pseudoprogression and hyperprogression. In connection with the presence of these phenomena, the clinicians have a serious question about the need to allocate a certain cohort of patients for whom therapy with immuno-oncological drugs will be most effective and safe. This review demonstrates research results describing mentioned phenomena.References
Collin M. Immune checkpoint inhibitors: a patent review (2010-2015) // Expert Opin Ther Pat. 2016 May;26(5):555-64.
Hodi F.S., Wolchok J.D. et al., Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial // Lancet Oncol. 2018 Nov;19(11):1480-1492.
Kim H., Comey S., Hausler K., Cook G. A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma // J Pharm Policy Pract. 2018 Feb 13;11:4.
Kanda S., Goto K., Shiraishi H. et al. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study // Ann. Oncol. 27 (12) (2016) 2242-2250.
P. Sharma P., Allison J.P. The future of immune checkpoint therapy // Science 348 (6230) (2015) 56-61.
Borghaei H., Paz-Ares L., Horn L. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer // N. Engl. J. Med. 373 (17) (2015) 1627-1639.
Herbst R.S., Baas P., Kim D.W. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYN0TE-010): a randomised controlled trial // Lancet. 2016 Apr 9;387(10027):1540-1550.
Plimack E.R., Bellmunt J., Gupta S. et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a nonrandomised, open-label, phase 1b study // Lancet Oncol. 18 (2) (2017) 212-220.
Chang L., Chang M., Chang F. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy // Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):15-21.
Schmidinger M. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma // Curr Opin Urol 2018;28(1):29-34.
Barata PC., Rini B. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin 2017;67(6):507-24. DOI: 10.3322/caac.21411
Ross K., Jones R.J. Immune checkpoint inhibitors in renal cell carcinoma // Clin Sci (Lond) 2017; 131(21): 2627-42.
Motzer R.J. et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial // J Clin Oncol. 2015; 33:1430-1437.
Motzer R.J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma // N Engl J Med. 2015; 373:1803-1813.
Beckermann K.E., Johnson D.B., Sosman J.A. PD-1/PD-L1 blockade in renal cell cancer // Expert Rev Clin Immunol. 2017 Jan;13(1):77-84.
Eisenhauer E.A., Therasse P., Bogaerts J. et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) // Eur. J. Cancer. 45, Nr. 2, Januar 2009, S. 228-47.
Wolchok J.D., Hoos A., Bohnsack O. et.al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria // Clin Cancer Res 2009; 15(23).
Nishino M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements // Clin Cancer Res. 2013 Jul 15; 19(14):3936-43.
Nishino M., Gargano M., Suda M. et al. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? // J Immunother Cancer. 2014; 2: 17.
Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers et al. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients //J Immunother Cancer. 2016; 4: 84.
Nishino M., Hatabu H., Hodi F.S. Imaging of cancer immunotherapy: current approaches and future directions // Radiology. 2019;290(1):9-22.
Katz S.I., Hammer M., Bagley S.J. et al. Radiologic pseudoprogression during anti-PD-1 therapy for advanced non-small cell lung cancer // J Thorac Oncol. 2018;13(7):978-986.
Ferrara R., Mezquita L, Texier M. et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy // JAMA Oncol. 2018;4(11):1543-1552.
Nishino M., Giobbie-Hurder A., Manos M.P. et al. Immune related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions // Clin Cancer Res. 2017;23(16):4671-4679.
Wolchok J.D., Hamid O., Ribas A. Atypical patterns of response in patients (pts) with metastatic melanoma treated withpembrolizumab (MK-3475) in KEYNOTE-001 // J Clin Oncol. 2015;33(15 supplement):3000.
Tanizaki J., Hayashi H., Kimura M. et al. Report of two cases of pseudoprogression in patients with non-small cell Lung Cancer treated with nivolumab-including histological analysis of one case after tumor regression // Lung Cancer 102 (2016) 44-48.
Sasaki A., Nakamura Y, Mishima S. et al. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced Gastric Cancer // Gastric Cancer. 2019;22(4):793-802.
Kanjanapan Y, Day D., Wang L. et al. Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities // Cancer. 2019;125(8):1341-1349.
Brower V. Hyperprogressive disease with anti-PD-1 and anti-PD-L1 // Lancet. Oncol 2016;17(12):e527.
Champiat S., Dercle L., Ammari S., et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 // Clin. Cancer Res. 2017;23(8):1920-28.
Ferte C., Fernandez M., Hollebecque A. et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trial // Clin. Cancer Res. 2014;20(1):246-52.
Lo Russo G., Moro M., Sommariva M. et al. AntibodyFc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade // Clin. Cancer Res. 2018.
Champiat S., Dercle L., Ammari S. et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 // Clin. Cancer Res. 23 (8) (2017) 1920-1928.
Saada-Bouzid E., Defaucheux C., Karabajakian A. et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma // Ann. Oncol. 28 (7) (2017) 1605-1611.
Ito K., Schoder H., Teng R. et al. Prognostic value of baseline metabolic tumor volume measured on 18F-fluo-rodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy // Eur J Nucl Med Mol Imaging. 2019;46(4):930-939.
Lee C.K., Man J., Lord S. et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis // J. Thorac. Oncol. 12 (2) (2017) 403-407.
Tawbi H.A., Burgess M., Bolejack V. et al. Pembroli-zumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial // Lancet Oncol. 18 (11) (2017) 1493-1501.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2020